A5022021966- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- PARP inhibition in cancer therapy
- Phagocytosis and Immune Regulation
- Erythrocyte Function and Pathophysiology
- Single-cell and spatial transcriptomics
- Glioma Diagnosis and Treatment
Princess Máxima Center
2021-2023
University of Helsinki
2022
Pediatric cancer is the leading cause of disease-related death in children and need for better therapeutic options remains urgent. Due to limited number patients, target drug development pediatrics often supplemented by data from studies focused on adult cancers. Recent evidence shows that pediatric cancers possess different vulnerabilities should be explored independently cancers.Using publicly available Genomics Drug Sensitivity Cancer database, we explore targets biomarkers specific solid...
Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss chromosome 11q MYCN amplification are two genetically distinct subsets neuroblastoma that associated poor patient outcome. Using an isogenic deleted model system high-throughput drug screening, we identify checkpoint kinase 1 (CHK1) as a potential target for neuroblastoma....
ABSTRACT Homozygous inactivation of the CDKN2A locus is one most common genomic aberrations in human cancer. The codes for two unrelated and distinctly regulated proteins: p14ARF p16INK4a, which inhibit MDM2 CDK4/6, respectively. Loss also a recurrent event relapsed neuroblastoma, childhood tumour that arises from neural crest cells. To examine consequences loss distinct gene transcripts we used CRISPR-Cas9 system to knockout p14, p16 p14 + SY5Y RNA sequencing transcriptome revealed striking...